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ABSTRACT
Objective Familial hypercholesterolaemia (FH) is 
a common inherited disorder causing premature 
coronary heart disease (CHD) and death. We have 
developed the novel Familial Hypercholesterolaemia 
Case Ascertainment Tool (FAMCAT 1) case- finding 
algorithm for application in primary care, to improve 
detection of FH. The performance of this algorithm 
was further improved by including personal history 
of premature CHD (FAMCAT 2 algorithm). This study 
has evaluated their performance, at 95% specificity, 
to detect genetically confirmed FH in the general 
population. We also compared these algorithms to 
established clinical case- finding criteria.
Methods Prospective validation study, in 14 general 
practices, recruiting participants from the general 
adult population with cholesterol documented. For 260 
participants with available health records, we determined 
possible FH cases based on FAMCAT thresholds, Dutch 
Lipid Clinic Network (DLCN) score, Simon- Broome criteria 
and recommended cholesterol thresholds (total cholesterol  
>9.0 mmol/L if  ≥30 years or  >7.5 mmol/L if  <30 years), 
using clinical data from electronic and manual extraction 
of patient records and family history questionnaires. The 
reference standard was genetic testing. We examined 
detection rate (DR), sensitivity and specificity for each 
case- finding criteria.
Results At 95% specificity, FAMCAT 1 had a DR of 27.8% 
(95% CI 12.5% to 50.9%) with sensitivity of 31.2% (95% 
CI 11.0% to 58.7%); while FAMCAT 2 had a DR of 45.8% 
(95% CI 27.9% to 64.9%) with sensitivity of 68.8% (95% 
CI 41.3% to 89.0%). DLCN score  ≥6 points yielded a DR 
of 35.3% (95% CI 17.3% to 58.7%) and sensitivity of 
37.5% (95% CI 15.2% to 64.6%). Using recommended 
cholesterol thresholds resulted in DR of 28.0% (95% CI 
14.3% to 47.6%) with sensitivity of 43.8% (95% CI 19.8% 
to 70.1%). Simon- Broome criteria had lower DR 11.3% 
(95% CI 6.0% to 20.0%) and specificity 70.9% (95% CI 
64.8% to 76.5%) but higher sensitivity of 56.3% (95% CI 
29.9% to 80.2%).
Conclusions In primary care, in patients with 
cholesterol documented, FAMCAT 2 performs 
better than other case- finding criteria for detecting 
genetically confirmed FH, with no prior clinical review 
required for case finding.
Trial registration number NCT03934320.
INTRODUCTION
Familial hypercholesterolaemia (FH) is 
an inherited cause of raised cholesterol 
resulting in premature coronary heart 
Key questions
What is already known about this subject?
 ► Over 80% of people with familial hypercholestero-
laemia (FH) still remain undiagnosed and untreated, 
but systematic searching of primary care health re-
cords can identify individuals at increased risk of FH 
and is recommended by national (National Institute 
for Health and Care Excellence, NICE) guidelines.
 ► The Familial Hypercholesterolaemia Case 
Ascertainment Tool (FAMCAT 1) algorithm, at a pre-
specified threshold related to prevalence of the con-
dition, has been shown to perform well at predicting 
patients with FH documented in primary care data-
bases, with the updated FAMCAT 2 algorithm per-
forming better at predicting these FH patients than 
the original version.
What does this study add?
 ► The FAMCAT 2 algorithm performed better at iden-
tifying genetically confirmed FH than the original 
version, yielding higher levels of detection and 
testing less individuals who did not have FH (higher 
sensitivity) in primary care. The Dutch Lipid Clinic 
Network criteria score   ≥6 points or using NICE- 
recommended cholesterol thresholds had lower de-
tection rates and sensitivity than FAMCAT 2 but still 
performed well, while the Simon- Broome criteria for 
possible FH showed limited detection rate and spec-
ificity in this setting.
How might this impact on clinical practice?
 ► FAMCAT 2 provides an automated method of 
searching individuals’ primary care electronic health 
records to yield higher numbers of subsequently ge-
netically confirmed FH than existing methods for 
case finding.
 ► Using routinely available health record data, FAMCAT 
2 offers the further advantage of minimising the 
need for prior clinical review and examination of 
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disease (CHD) and greatly increased mortality risk, 
when left untreated.1–3 In most countries, over 80% of 
people with FH remain undiagnosed.4 5 This presents a 
major challenge for health systems, with as many as 1 in 
250 people affected.6 Existing international guidelines 
recommend clinicians use clinical tools such as Dutch 
Lipid Clinic Network (DLCN) score or Simon- Broome 
criteria to detect possible FH, prior to definitive genetic 
testing.4 7 8 However, in addition to cholesterol measures, 
all these tools require detailed family histories of hyper-
cholesterolaemia and premature CHD and examination 
for physical signs of FH, to be undertaken.1 9 This makes 
them less useful for case- finding in the general commu-
nity population. Recent UK guidelines have additionally 
recommended systematically identifying potential cases 
through searching primary care electronic healthcare 
records (EHRs) for patients using certain cholesterol 
thresholds (under 30 years old with cholesterol over 7.5 
mmol/L or over 9.0 mmol/L in older patients), roughly 
aligned to the 99th population centile for cholesterol 
levels in the general population.7 Further consideration 
is that these primary care FH case- finding tools, used to 
identify initial possible FH cases, should have high speci-
ficity to ensure that most of those with actual FH are not 
missed.
Current systematic approaches to identify FH in 
primary care records only identify a minority of patients 
with FH.10–13 To improve detection of the majority of 
individuals still not diagnosed with the condition, we 
developed a Familial Hypercholesterolaemia Case Ascer-
tainment Tool (FAMCAT).14–16 The FAMCAT algorithm 
takes account of the interaction between family history, 
statin prescribing, triglycerides and secondary causes, 
and focuses on those factors that are readily extractable 
from routine entries in patients’ EHRs, searching the 
available data to identify those with highest likelihood of 
FH. It is intended as a case- finding tool to identify those 
eligible for further assessment, specialist referral and 
genetic testing for possible FH.
The FAMCAT 1 algorithm was originally derived and 
internally validated using data from 3 million patients 
in UK primary care using the Clinical Practice Research 
Datalink—broadly representative of the UK general 
population in terms of sex, age and ethnicity. It includes 
elements of existing clinical criteria tools, such as DLCN 
and Simon- Broome, in addition to other variables such 
as triglyceride level, and clinical diagnosis of diabetes 
and chronic kidney disease based on coded records, to 
improve diagnostic accuracy.14 FAMCAT has been further 
externally validated in two large UK primary care popu-
lation studies.15 16 These three previous studies showed 
FAMCAT was highly predictive of FH documented in 
primary care records with similar performance (area 
under the curve (AUC) between 0.83 to 0.86). A further 
advancement of the algorithm has been developed 
(FAMCAT 2) by incorporating past history of premature 
CHD, leading to an improved AUC of 0.87.15 We origi-
nally evaluated the FAMCAT 1 and FAMCAT 2 algorithms 
at an FH probability threshold of 0.002 which aligns to 
the original estimated FH prevalence of 1 in 500. This 
prevalence is now accepted to be 1 in 250.6 In this study, 
to optimise the clinical value of the FAMCAT 1 and 2 case- 
finding algorithms, we estimated the performance and 
probability threshold of these algorithms at 95% speci-
ficity, using FH genetic testing as the reference standard. 
Further, we compared the performance of the algorithms 
at this specificity against established case- finding criteria 
(DLCN, Simon- Broome and recommended cholesterol 
threshold) in this population.
METHODS
Study population
Twenty- three General Practices, in the catchment areas of 
two East Midland’s lipid specialist services, expressed an 
interest to participate with 14 general practices recruited 
from May 2017 to November 2019, with a total practice 
population of 193 589. To ensure diverse study popula-
tions were recruited, five general practices predominately 
serving urban areas were recruited, together with four 
serving suburban areas and four from rural areas. The 
updated FH case- finding tool, incorporating FAMCAT 
2, was installed on practice computers as part of a free- 
to- use FH audit tool in primary care17 and used to iden-
tify potentially eligible patients who were then offered 
genetic blood testing for FH.
Participants
Participants were eligible if they were aged 18 years or 
over, had a serum cholesterol recorded in their EHRs, 
without a previous diagnosis of FH.
Participants were invited for genetic testing if identi-
fied by the practice administrator to have FAMCAT prob-
ability of FH above 0.002 (0.2%, as defined in previous 
studies of FAMCAT14 15 based on an EHRs search. For 
all participants with access to their EHR who under-
went confirmatory genetic testing, we recalculated the 
FAMCAT 1 probability threshold score and calculated 
the FAMCAT 2 and DLCN scores, together with Simon- 
Broome criteria, confirming and expanding the informa-
tion already collected through manual review of EHRs 
and further verified by a validated family history ques-
tionnaire (seeonline supplemental file 1).18 Use of any of 
these criteria, except for FAMCAT 1 and 2, for case finding 
is recommended in current English (National Institute 
for Health and Care Excellence, NICE) guidelines for 
best practice.7 The data captured included all FAMCAT 
variables, and data used for other clinical case finding 
criteria: Simon- Broome criteria variables (total and low- 
density lipoprotein cholesterol (LDL- C), family history of 
premature CHD and/or hypercholesterolaemia, clinical 
signs of FH), DLCN criteria variables (LDL- C, clinical 
history of coronary heart, cerebrovascular and peripheral 
vascular disease, family history, clinical signs of FH).4 Full 
details of the variables for each case- finding criteria are 
given in online supplemental table 1.
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FAMCAT algorithms
The original (FAMCAT 1) algorithm consists of nine 
diagnostic indicators stratified by gender.14 This includes 
total cholesterol (TC) or LDL- cholesterol, age during 
cholesterol measurement, triglycerides, lipid- lowering 
drug usage, family history of FH, family history of CHD, 
family history of raised cholesterol, diabetes and chronic 
kidney disease. Full details of variables are provided in 
online supplemental table 1.
A subsequent version of the algorithm (FAMCAT 2), 
also included coded personal history of premature CHD 
and re- estimated the regression equations with TC, LDL- 
cholesterol, triglycerides and age as continuous variables 
to improve its calibration.15 The regressions functions 
and equations are fully published elsewhere.15
Reference standard
Confirmed FH was defined as a laboratory determined 
pathogenic variant (designated here as a mutation) 
in LDLR, APOB, PCSK9 or LDLRAP1 identified. The 
genetic testing was conducted by the Bristol National 
Health Service (NHS) Genetics Laboratory, using a next- 
generation sequencing assay covering all coding exons 
and intron–exon boundaries of LDLR, APOB and PCSK9 
plus a assay for copy number variants for LDLR inser-
tions/deletions. The report outputs also identified vari-
ants of unknown significance (VUS). The laboratory staff 
conducting genetic testing were blinded to the FAMCAT 
scores, cholesterol levels, DLCN score and Simon- Broome 
classification of the participants.
Patient and public involvement
Our patient and public study coinvestigator was involved 
in the design and conduct of this study. The patient repre-
sentatives participated in interpreting the study results 
and assisted with the plain English summary.
Statistical analysis
We compared the characteristics of male and female 
recruited participants. The detection rate of genetically 
confirmed FH at optimal probability thresholds were 
estimated for the FAMCAT 1 and FAMCAT 2 algorithms, 
Simon- Broome criteria for possible FH, DLCN score 
≥6 and recommended TC thresholds alone ( TC >9.0 
mmol/L in those 30 years +; TC  >7.5 in those under 30 
years, approximating to the 99th centile for the general 
population). The optimal threshold was defined as that 
achieved at a specificity of 95% (ie, only missing 1 in 20 
patients with FH). The analysis was also performed at a 
specificity of 90% specificity. The probability threshold 
is the cut- off where high risk of FH is defined and was 
varied from 0.002 to 0.25. Further the sensitivity, speci-
ficity, positive predictive value (PPV) and negative predic-
tive value (NPV), and the AUC were calculated. For all 
performance metrics, 95% CIs were calculated based 
on Wilson score interval method.19 PPV and NPV were 
calculated based on the study prevalence of genetically 
confirmed FH. All analyses were conducted using STATA 
V.16.1.




From a total adult population of 193 589 patients from 
14 general practices, 86 219 (44.4%) had a TC or LDL- C 
assessed and documented in their EHRs. Full clinical data 
from the EHR was available for 260 study participants 
(figure 1), of which 16 participants were identified with 
a confirmed FH mutation (13 LDLR, 3 APOB, 1 PCSK9), 
10 participants were identified with a VUS, while 234 
participants (90%) did not have a known FH pathogenic 
mutation or documented as VUS. These VUS results were 
reviewed by three experts and they confirmed none were 
consistent with known FH pathogenic mutations.
Characteristics of recruited participants
The average age of the 260 recruited participants was 
57.5 years, 80% self- reported as white British and 69% 
were women. Twenty- five per cent of participants had a 
statin prescribed and 50% had a family history of prema-
ture CHD in first- degree relatives. As demonstrated in 
table 1, women were older and had lower FAMCAT prob-
ability scores.
Figure 1 Study flow diagram. EHR, Electronic Health 
Records; FH, familial hypercholesterolaemia; FHQ, family 
history questionnaire; VUS, variant of unknown significance.
copyright.
 on O
















4 Qureshi N, et al. Open Heart 2021;8:e001752. doi:10.1136/openhrt-2021-001752
Performance of FAMCAT 1 and FAMCAT 2 algorithms
At 95% specificity, the FAMCAT 1 algorithm achieved a 
detection rate of 27.8% (95% CI 12.5% to 50.9%) and 
sensitivity of 31.2% (95% CI 11.0% to 58.7%), with an 
FH probability threshold of 0.140 (figure 2). With a 
specificity of 90%, the detection rate dropped slightly to 
25.0% (95% CI 13.3% to 42.1%) but sensitivity increased 
to 50.0% (95% CI 24.7% to 75.3%), with a probability 
threshold of 0.080. In the case of the FAMCAT 2 algo-
rithm, at 95% specificity the detection rate was 45.8% 
(95% CI 27.9% to 64.9%) and sensitivity of 68.8% (95% 
CI 41.3% to 89.0%), with a probability threshold of 0.005 
(figure 2). With a specificity of 90%, the detection rate 
dropped to 30.6% (95% CI 18.0% to 46.9%) with iden-
tical sensitivity 68.8% (95% CI 41.3% to 89.0%), with a 
probability threshold of 0.004. Full details on all metrics 
at the different thresholds of the FAMCAT 1 and FAMCAT 
2 is presented in online supplemental table 2.
From the 260 participants completing genetic testing, 
and health records available, 32 participants had 
FAMCAT probability scores below the original study 
selection criteria (probability at or above 0.002). Online 
supplemental table 3 and online supplemental figure 
1 present the full performance metrics when these 32 
participants were excluded. When limited to 228 partic-
ipants, at 95% specificity for FAMCAT 1 algorithm, the 
detection rate was 28.6% (95% CI 11.7% to 54.7%) and 
sensitivity 25.0% (95% CI 7.3% to 52.4%)), with a similar 
probability threshold of 0.160 and the FAMCAT 2 algo-
rithm had similar detection rate (50.0% (95% CI 29.9% 
to 70.1%)), sensitivity 62.5% (95% CI 35.4% to 84.8%) 
and probability threshold (0.005).
Comparison to other case-finding tools
By applying English NICE recommendations for case- 
finding to the genetic tested individuals, the performance 
of Simon- Broome, DLCN and cholesterol thresholds 
could be assessed and compared with FAMCAT 1 and 2 
(table 2). The Simon- Broome criteria had a substantially 
lower detection rate of 11.3% (95% CI 6.0% to 20.0%), 
only identifying 9 cases from 80 fulfilling the criteria, with 
a sensitivity of 56.3% (95% CI 29.9% to 80.2%) and spec-
ificity of 70.9% (95% CI 64.8% to 76.5%). The DLCN 
≥6 points had a higher detection rate of 35.3% (95% CI 
17.3% to 58.7%) and specificity of 95.5% (95% CI 92.1% 
to 97.7%) but lower sensitivity (37.5%, 95% CI 15.2% to 
64.6%); and the recommended cholesterol thresholds 
had a similar detection rate of 28.0% (95% CI 14.3% to 
47.6%) with sensitivity of 43.8% (95% CI 19.8% to 70.1%) 
and a specificity of 92.6% (95% CI 88.6% to 95.6%). PPV 
ranged from 10.3% (Simon- Broome) to 43.4% (FAMCAT 
2), with a high NPV maintained of at least 96%.
DISCUSSION
Principal findings
By comparing the performance of the FAMCAT algo-
rithms against the reference standard of an FH genetic test, 
we identified that the FAMCAT 2 algorithm performed 
better than the original version, yielding higher levels of 






Age, years* median (IQR) 53.0 (46.0–59.0) 59.0 (51.5–66.5) <0.0001
Highest total cholesterol, mmol/L
median (IQR)
7.4 (6.6–8.0) 7.7 (6.8–8.3) 0.023
Median highest Low- density lipoprotein cholesterol, mmol/L median (IQR) 5.0 (4.0–5.3) 5.1 (4.3–5.7) 0.047
Family history of premature coronary heart disease† 41 (51.3) 89 (49.4) 0.788
Statin prescribed 24 (30%) 42 (23%) 0.254
FAMCAT 1 probability of FH, median (IQR) 0.047 (0.20–0.091) 0.010 (0.003–0.217) <0.0001
Fulfils Simon- Broome possible FH criteria‡ 21 (26.3%) 59 (32.8%) 0.293
P value, Mann- Whitney U test for continuous variables and χ2 test for categorical variables.
*Age at time of recruitment into the study.
†Premature defined as coronary heart disease  <50 years in second- degree relative or  <60 years in first- degree relative.
‡Simon- Broome possible FH criteria defined as having a total cholesterol  >7.5 mmol/L or LDL- C  >4.9 mmol/L and a family history of premature coronary heart 
disease.
FAMCAT, Familial Hypercholesterolaemia Case Ascertainment Tool; FH, familial hypercholesterolaemia.
Figure 2 Receiver operating characteristic curve and 
sensitivity of FAMCAT 1 and FAMCAT 2 algorithms at 95% 
specificity (n=260). AUC, area under the curve; FAMCAT, 
Familial Hypercholesterolaemia Case Ascertainment Tool.
copyright.
 on O















5Qureshi N, et al. Open Heart 2021;8:e001752. doi:10.1136/openhrt-2021-001752
Cardiac risk factors and prevention
detection and sensitivity. Also, comparisons against the 
DLCN criteria score  ≥6 points or using the NICE recom-
mended cholesterol thresholds had lower detection rates 
and sensitivity than FAMCAT 2 but still performed well, 
while the Simon- Broome criteria for possible FH showed 
limited detection rate and specificity in this setting.
Comparison with existing studies
This is the first study, internationally, to evaluate and 
compare case- finding approaches for FH in the primary 
care population, confirmed with genetic diagnosis as the 
primary outcome. Existing evidence on case finding in the 
community has been limited to using clinical phenotype 
as the FH primary outcome of interest.10 11 13 20 As would 
be expected, when identifying genetically confirmed FH 
in primary care, there was lower detection rates than 
elicited in specialist settings, such as lipid clinics, where 
genetic detection rates of 20%–38% is achieved using the 
possible Simon- Broome criteria and up to 41% detection 
in those with DLCN scores greater than or equal to 6.21–23 
Further, electronic case finding for FH using DLCN 
criteria requires specific clinical findings to have been 
recorded (tendon xanthoma, premature arcus corne-
alis) to complete the assessment, which is uncommon in 
primary care.4 24 Previous studies in primary care have 
thus required FH nurse specialists to identify these clin-
ical signs.25 26
Strengths and limitations
This study has several strengths. The FAMCAT algorithm 
has been validated against genetic testing in a national 
diagnostic laboratory. The research has also been prag-
matically undertaken in a routine primary care setting. 
General practitioners were left to identify patients eligible 
for genetic testing for FH using the FAMCAT algorithm. 
This supports the fidelity of the approach, and its gener-
alisability to usual clinical practice. In contrast, many 
commonly used clinical algorithms for risk stratification 
and prediction have not been validated in their intended 
settings, being solely based on retrospective modelling 
before their adoption in guidelines for practice.27 28
The genetic testing used is gold- standard diagnostic 
confirmation of FH conducted by accredited English 
NHS laboratories. We only classified patients with FH 
if they had a clearly identified pathogenic variant for 
FH in their laboratory results. The capture of clinically 
coded data from patient electronic records, confirma-
tion of family history using a validated questionnaire, 
and further manual record extraction in practice allowed 
for triangulation and improved validity of the clinical 
variables used in the case- finding criteria. This ensured 
accurate comparisons between FH case- finding criteria, 
including Simon- Broome and DLCN criteria, and choles-
terol thresholds.1 4 7 The inclusion of patients below the 
initial 0.002 thresholds for all of the five criteria enabled 
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We recognise some study limitations. In the study, 
patients had to have a prior cholesterol measurement 
to be included in the study, so the recruitment strategy 
would have missed those who may have FH but never had a 
cholesterol measurement. Further, our study participants 
expectedly had overall higher cholesterol levels than the 
general primary care population. However, in real- world 
setting, the starting point for any FH case- finding tool will 
usually be those patients with serum cholesterol recorded 
in their primary care EHRs with a focus on those with 
higher cholesterol concentrations. Recognising patients 
40 years and over would have had cholesterol testing as 
part of the national cardiovascular disease (CVD) health 
check programme, while those under 40 are unlikely to 
be measured unless clinical indicated, a subgroup anal-
ysis stratified at 40 would have been informative but too 
few participants with cholesterols below 40 years (n=23) 
were available to enable a meaningful analysis. Also, in 
this study, we collated comprehensive family histories 
leading to a significant proportion of patients with a 
family history of premature CHD being identified. This 
highlights the importance of improved family history 
recording in primary care and the benefits of targeted 
case- finding and assessment to those patients at greatest 
risk.
Clinical implications
The current failure to diagnose the majority of people with 
FH leads to either no treatment or inadequate treatment 
of people wrongly thought to have commoner ‘life- style 
related’ elevated cholesterol. As a result, patients with unde-
tected FH will suffer avoidable premature CVD and higher 
risk of early death. FAMCAT provides an automated method 
of searching patients’ EHRs to subsequently yield higher 
numbers of genetically confirmed FH than existing methods 
for case finding. Using routinely available health record data, 
FAMCAT offers the further advantage of not requiring the 
collection of new information or prior clinical review and 
examination of patients. It can thus be used as a case- finding 
tool to more efficiently identify adults with possible FH in 
the community and streamline referrals for further specialist 
assessment and genetic testing.29 This novel approach 
appears superior to case- finding using the Simon- Broome 
criteria, which was developed from historical secondary care 
data. This should be coordinated with other models for case- 
finding, cascade testing of relatives and child screening.4 7 9 28
To optimise FH identification in primary care, the 
initial FH case finding tool should maximise specificity, 
to avoid missing FH patients. Therefore, the perfor-
mance of the FAMCAT 1 and FAMCAT 2 was assessed at 
specificity of 90% and 95%. If healthcare resources are 
limited, probability of FH thresholds could be altered 
to improve the FH cases detection rate and reduce 
numbers sent for genetic testing but this would be at the 
expense of missing FH patients. This study also supports 
this decision making, by providing details of the sensi-
tivity and specificity at different FAMCAT probability 
thresholds. With global interest in primary prevention of 
CVD, increasing numbers of adults will have cholesterol 
measurements, increasing the opportunity to apply the 
FAMCAT algorithm in EHRs. Fundamentally, FAMCAT 
and other primary care case- finding criteria need the 
cholesterol measurement available and this cannot be 
imputed into the algorithm.30 Also the primary care EHRs 
need to be kept up- to- date with key variables, such as, the 
family history.31 32 Those patients with a family history of 
premature CHD should have this information coded in 
their records and recalled for cholesterol testing. Further 
research on the implementation of FAMCAT in practice 
is now warranted.
CONCLUSIONS
We have demonstrated that in primary care, in patients 
with raised cholesterol levels documented in medical 
records, this new case- finding algorithm (FAMCAT) 
performs better than DLCN score, Simon- Broome criteria 
or cholesterol thresholds alone for detecting genetically 
confirmed FH, with no prior clinical review or examina-
tion required for case finding.
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Supplementary Table 1:  Availability of standard diagnostic criteria variables in 
manual extraction from EHR 
 
Score Number (%) 
Dutch Lipid Criteria Network (DLCN) 
Family History   
First-degree relative with premature coronary and/or 
vascular disease (men ≤ 55 years, women ≤ 60 year) 
1 130 (50%) 
First-degree relative with known LDL-C ≥ 95th percentile 
for age and sex 
1 - 
Clinical history   
Patient with premature coronary artery disease (men ≤ 
55 years, women ≤ 60 years) 
2 22 (8.5) 
Patient with premature cerebral or peripheral vascular 
disease (men ≤ 55 years, women ≤ 60 years) 
1 4 (1.5) 
Physical examination   
Tendon xanthomata 6 0 
Arcus cornealis at age ≤ 45 years 4 0 
LDL cholesterol level (mmol/L)   
≥ 8.5 8 4 (1.5) 
6.5 – 8.4 5 14 (5.4) 
5.0 – 6.4 3 121 (46.5) 
4.0 – 4.9 1 59 (22.7) 
Simon Broome Diagnostic criteria 
Family History   
Family history of myocardial infarction: aged younger 
than 50 years in second-degree relative or aged younger 





Family history of raised total cholesterol: greater than 7.5 
mmol/l in adult first- or second-degree relative)  
- 37 (14.2) 
Clinical history   
Patient with premature coronary artery disease (men ≤ 
55 years, women ≤ 60 years) 
- 22 (8.5) 
Physical examination   
Tendon xanthomata - 0 
Cholesterol level   
Total cholesterol > 7.5mmol/l or LDL-Cholesterol > 4.5 
mmol/l 
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Continuation of Supplementary Table 1… 
 Score Number (%) 
FAMCAT 1 algorithm 
Highest total or LDL cholesterol (mmol/L) -  
Ideal (TC ≤ 5 or LDL ≤ 3.3)   27 (10.4) 
High (TC>5 to ≤6.5 OR LDL>3.3 to ≤4.1)   30 (11.5) 
Very High (TC>6.5 to ≤7.5 OR LDL>4.1 to ≤4.9)   53 (20.4) 
Extremely High (TC>7.5 OR LDL>4.9)   150 (57.7) 
Age during cholesterol measurement (years) -  
16-24   3 (1.2) 
25-34   12 (4.6) 
35-44   40 (15.4) 
45-54   75 (28.9) 
55-64   75 (28.9) 
65-74   47 (18.1) 
75-84   8 (3.1) 
85 or above  0 
Triglycerides (mmol/L) -  
Ideal (<1.7)   127 (48.9) 
Borderline high (≥1.7 to<2.3)  51 (19.6) 
High (≥2.3 to<5.6)   68 (26.2) 
Very high (≥5.6)   7 (2.7) 
Not Recorded  7 (2.7) 
Treatment with lipid lowering drugs during cholesterol 
measurement 
-  
No lipid lowering drugs prescribed  194 (74.6) 
Low potency statins  2 (0.8) 
Medium potency statin  47 (18.1)  
High potency statins  17 (6.5) 
Family history of myocardial infarction  - 131 (50.4) 
Family history of raised cholesterol  - 37 (14.2) 
Family history of familial hypercholesterolaemia  - 9 (3.5) 
Any diagnosis of diabetes  - 16 (6.2) 
Any diagnosis of kidney disease  - 7 (2.7) 
FAMCAT 2 algorithm  
Highest LDL cholesterol ever (mmol/L), median (IQR) - 5.0 (4.2 – 5.6) 
Highest total cholesterol ever (mmol/L), median (IQR)  7.6 (6.7 – 8.2) 
Age during cholesterol measurement (years), mean (SD) - 53.9 (12.1) 
Triglycerides (mmol/L), mean (SD) - 1.7 (1.3 – 2.5) 
Previous history of premature myocardial infarction - 22 (8.5) 
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Supplementary Table 2.  FAMCAT performance (detection rate, sensitivity, specificity, positive and negative predictive values, AUC) for 























0.002 16/228 0/32 7.0% (4.4 – 11.1%) 100% 13.1% (0.1 – 18.0%) 6.4% (5.7 – 6.8%) 100% 0.57 (0.54 – 0.59) 
0.004 16/200 0/60 8.0% (5.0 – 12.6%) 100%  24.6% (19.3 – 30.5%) 7.3% (6.8 – 7.8%) 100%  0.63 (0.60 – 0.65) 
0.010 16/159 0/101 10.1% (6.3 – 15.7%) 100%  41.4% (35.1 – 47.9%) 9.2% (8.4 – 10.1%) 100%  0.71 (0.68 – 0.74) 
0.050 11/54 5/206 20.4% (11.8 – 32.9%) 68.8% (41.3 – 89.0%) 82.4% (77.0 – 86.9%) 18.8% (12.9 – 25.7%) 97.8% (95.6 – 98.8%) 0.76 (0.64 – 0.88) 
0.080 8/32 8/228 25.0% (13.3 – 42.1%) 50.0% (24.7 – 75.3%) 90.2% (85.7 – 93.6%) 23.2 (13.9 – 35.2%) 96.8% (95.0 – 98.0%)  0.70 (0.57 – 0.83) 
0.100 6/22 10/238 27.3% (13.2 – 48.2%) 37.5% (15.2 – 64.6%) 93.4% (89.6 – 96.2%) 25.3% (13.6 – 41.9%) 96.2% (94.6 – 97.4%) 0.65 (0.53 – 0.78) 
0.140 5/18 11/242 27.8% (12.5 – 50.9%) 31.3% (11.0 – 58.7%) 94.7% (91.1 – 97.1%) 25.8% (12.8 – 45.2%) 95.9% (94.4 – 97.0%) 0.63 (0.51 – 0.75) 
0.150 5/16 11/244 31.3% (14.2 – 55.6%) 31.3% (11.0 – 58.7%) 95.5% (92.1 – 97.7%) 29.1% (14.4 – 49.9%) 95.9% (94.5 – 97.1%) 0.63 (0.52 – 0.75) 
0.200 3/9 13/251 33.3% (12.1 – 64.6%) 18.8% (4.0 – 45.6%) 97.5% (94.7 – 99.1%) 31.1% (12.1 – 60.5%) 95.3% (94.2 – 96.3%) 0.58 (0.48 – 0.68) 
0.250 2/5 14/255 40.0% (11.8 – 76.9%) 12.5% (1.6 – -38.3%) 98.8% (96.4 – 99.7%) 37.6% (11.5 – 74.1%) 95.0% (94.1 – 96.0%) 0.56 (0.47 – 0.64) 
FAMCAT 2 
0.002 12/79 4/181 15.2% (8.9 – 24.7%) 75.0% (47.6 – 92.7%) 72.5% (66.5 – 78.0%) 13.9% (10.0 – 18.3%) 98.0% (95.4 – 99.0%) 0.74 (0.62 – 0.85) 
0.0036 11/36 5/224 30.6% (18.0 – 46.9%) 68.6% (41.3 – 89.0%) 89.8% (85.2 – 93.3%) 28.5% (19.1 – 38.7%) 98.0% (95.9 – 98.9%) 0.79 (0.67 – 0.91) 
0.004 11/29 5/231 37.9% (22.7 – 56.0%) 68.8% (41.3 – 89.0%) 92.6% (88.6 – 95.6%) 35.6% (23.5 – 47.9%) 98.0% (96.0 – 99.0%) 0.81 (0.69 – 0.93) 
0.0047 11/24 5/236 45.8% (27.9 – 64.9%) 68.8% (41.3 – 89.0%) 94.7% (91.1 – 97.1%) 43.4% (28.3 – 57.4%) 98.1% (96.1 – 99.0%) 0.82 (0.70 – 0.94) 
0.010 8/10 9/250 80.0% (49.0 – 94.3%) 50.0% (24.7 – 75.3%) 99.2% (97.1 – 99.9%) 78.3% (43.7 – 91.6%) 97.1% (95.4 – 98.2%) 0.75 (0.62 – 0.87) 
0.050 3/3 13/257 100%  18.8% (4.0 – 45.6%) 100%  100% 95.4% (94.3 – 96.4%) 0.59 (0.49 – 0.69) 
0.100 2/2 14/258 100% 12.5% (1.6 – 38.3%) 100% 100% 95.1% (94.2 – 96.0%) 0.56 (0.48 – 0.65) 
 
* Positive predictive value (PPV) and negative predictive value (NPV) assumes a prevalence of familial hypercholesterolaemia (FH) of 0.056 based on study. 
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AUC – area under the curve; CI – confidence interval; FH – familial hypercholesterolaemia; NPV – negative predictive value; PPV – positive predictive value. 
Detection rate - 95% confidence interval calculated using the Wilson score interval discussed in Brown, LD, Cat, TT and DasGupta, A (2001). Interval Estimation for a proportion. Statistical Science 16:101-133. 
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Supplementary Table 3.  FAMCAT performance (detection rate, sensitivity, specificity, positive and negative predictive values, AUC) for 























0.004 16/200 0/28 8% (5.0 – 12.6%) 100% 13.2% (9.0 – 18.5%) 6.4% (5.7 – 6.8%) 100% 0.57 (0.54 – 0.59) 
0.010 16/159 0/69 10.1% (6.3 – 15.7%) 100% 32.5% (26.3 – 39.3%) 8.1% (7.0 – 8.8%) 100% 0.66 (0.63 – 0.69) 
0.050 11/54 5/174 20.4% (11.8 – 32.9%) 68.8% (41.3 – 89.0%) 79.7% (73.7 – 84.9%) 16.7% (11.4 – 23.1%) 97.7% (95.4 – 98.8%) 0.74 (0.62 – 0.86) 
0.085 8/30 8/198 26.6% (14.2 – 44.5%) 50.0% (24.7 – 75.3%) 89.6% (84.7 – 93.4%) 22.2% (13.2 – 34.2%) 96.8% (94.9 – 98.0%) 0.70 (0.57 – 0.83) 
0.100 6/22 10/206 27.3% (13.2 – 48.2%) 37.5% (15.2 – 64.4%) 92.5% (88.0 – 95.6%) 22.8% (12.0 – 38.5%) 96.1% (94.5 – 97.3%) 0.65 (0.53 – 0.77) 
0.160 4/14 12/214 28.6% (11.7 – 54.7%) 25.0% (7.3 – 52.4%) 95.3% (91.5 – 97.7%) 23.9% (10.6 – 46.1%) 95.5% (94.2 – 96.7%) 0.60 (0.49 – 0.71) 
0.150 5/16 11/212 31.3% (14.2 – 55.6%) 31.3% (11.0 – 58.7%) 94.8% (90.9 – 97.4%) 26.3% (12.8 – 46.3%) 95.9% (94.4 – 97.0%) 0.63 (0.51 – 0.75) 
0.200 3/9 13/219 33.3% (12.1 – 64.6%) 18.8% (4.0 – 45.6%) 97.2% (93.9 – 99.0%) 28.2% (10.7 – 57.1%) 95.3% (94.2 – 96.3%) 0.58 (0.48 – 0.68) 
0.250 2/5 14/223 40.0% (11.8 – 76.9%) 12.5% (1.6 – 38.3%) 98.6% (95.9 – 99.7%) 34.4% (10.2 – 71.4%) 95.0% (94.1 – 96.0%) 0.56 (0.47 – 0.64) 
FAMCAT 2 
0.002 12/78 4/150 15.4% (9.0 – 25.0%) 75.0% (47.6 – 92.7%) 68.9% (62.2 – 75.0%) 12.5% (9.0 – 16.5%) 97.9% (95.2 – 99.0%) 0.72 (0.61 – 0.83) 
0.0038 11/33 5/195 33.3% (19.8 – 50.4%) 68.6% (41.3 – 89.0%) 89.6% (84.7 – 93.4%) 28.2% (18.6 – 38.8%) 98.0% (95.9 – 98.9%) 0.79 (0.67 – 0.91) 
0.004 11/28 5/200 39.3% (23.6 – 57.6%) 68.8% (41.3 – 89.0%) 92.0% (87.5 – 95.3%) 33.7% (21.9 – 46.0%) 98.0% (96.0 – 99.0%) 0.80 (0.68 – 0.92) 
0.0047 10/20 6/208 50.0% (29.9 – 70.1%) 62.5% (35.4 – 84.8%) 95.3% (91.5 – 97.7%) 44.0% (27.0 – 59.9%) 97.7% (95.8 – 98.7%) 0.79 (0.67 – 0.91) 
0.010 8/10 8/218 80.0% (49.0 – 94.3%) 50.0% (24.7 – 75.3%) 99.1% (96.6 – 99.9%) 75.9% (40.3 – 90.4%) 97.1% (95.4 – 98.2%) 0.75 (0.62 – 0.87) 
0.050 3/3 13/225 100% 18.8% (4.0 – 45.6%) 100% 100% 95.4% (94.3 – 96.4%) 0.59 (0.49 – 0.69) 
0.100 2/2 14/226 100% 12.5% (1.6 – 38.3%) 100% 100% 95.1% (94.2 – 96.0%) 0.56 (0.48 – 0.65) 
 
* Positive predictive value (PPV) and negative predictive value (NPV) assumes a prevalence of familial hypercholesterolaemia (FH) of 0.056 based on study. 
AUC – area under the curve; CI – confidence interval; FH – familial hypercholesterolaemia; NPV – negative predictive value; PPV – positive predictive value. 
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Detection rate - 95% confidence interval calculated using the Wilson score interval discussed in Brown, LD, Cat, TT and DasGupta, A (2001). Interval Estimation for a proportion. Statistical Science 16:101-133. 
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Supplementary Figure 1: ROC curve and sensitivity of FAMCAT 1 & FAMCAT2 algorithms at 
95% specificity (n=228) 
 
 








BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart
 doi: 10.1136/openhrt-2021-001752:e001752. 8 2021;Open Heart, et al. Qureshi N
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart
 doi: 10.1136/openhrt-2021-001752:e001752. 8 2021;Open Heart, et al. Qureshi N
Participant number (for research purposes):  
© The University of Nottingham 2017. All rights reserved. Applications for the copyright owner’s permission to modify any part 
of this publication should be forwarded in writing to Professor Nadeem Qureshi, Primary Care, School of Medicine, Queen’s 
Medical Centre, Derby Road, Nottingham NG7 2U     

























BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart
 doi: 10.1136/openhrt-2021-001752:e001752. 8 2021;Open Heart, et al. Qureshi N
Participant number (for research purposes):  
© The University of Nottingham 2017. All rights reserved. Applications for the copyright owner’s permission to modify any part of this publication should be forwarded in writing to Professor 
Nadeem Qureshi, Primary Care, School of Medicine, Queen’s Medical Centre, Derby Road, Nottingham NG7 2U         




This section asks about your IMMEDIATE RELATIVES Do not give information about family members who are not your blood relatives e.g. step- or 



















Yes or No 
 
Any history of 
HEART ATTACK or 
MYOCARDIAL 
INFARCTION (MI) 
Please state Yes or No 
 
 
Age when first 
HEART 






Yes or No 
 












         
Your father 




         
Your mother’s 
father 
         
Your father’s 
mother 
         
Your father’s 
father 
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 How many of the following blood relatives do you have (including any who have died)? 
 Please put the number in the box. If you are unsure of the exact number, please put an approximate number. 
. 
 On your mother’s side On your father’s side 
Brothers (include half brothers) Uncles: Uncles: 
Sisters (include half sisters) Aunts: Aunts: 
Sons *    
Daughters *    
       * Complete this only for sons and daughters for whom you are the biological parent. 
 You do not need to give any more information about living relatives, unless they have a history of raised 
cholesterol, have had heart disease or heart operations 
  Please give details on the following sheets for relatives  
 who have had heart attack, also known as Myocardial Infarction (MI) 
 who have, or have had, angina 
 who have died   
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or year of birth 
 




Yes or No 
 
 
Any history of 
HEART ATTACK or 
MYOCARDIAL 
INFARCTION (MI) 










Any history of 
ANGINA 
Please state 
Yes or No 
 












         
          
          










         
         
         
         
          
Please use the last sheet of this questionnaire if you require more space for your answers about brothers and sisters 
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This section asks about illnesses in more distant BLOOD RELATIVES 
 













First name (optional) 
 
Approximate age, 
or year of birth 
 




Yes or No  
 
Any history of 
HEART ATTACK or 
MYOCARDIAL 
INFARCTION (MI) 














Yes or No 
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This section asks about illnesses in your sons and daughters 
 
 
Relationship to you 
 
 
First name (optional) 
 
Approximate age, 
or year of birth  
 




Yes or No 
 

















Yes or No 
 
If this person 




What was the cause of death? 
Your sons          
         
        
Your daughters         
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Put M for 
mother’s 








age, or year of 
birth 
 




Yes or No 
 




Please state Yes or 
No  
 
Age when first 
HEART 














What was the cause of 
death? 
 
          
          
          
 
PLEASE USE THIS SPACE BELOW IF YOU REQUIRE MORE SPACE FOR ANY OF YOUR ANSWERS OR TO GIVE ANY 
COMMENTS 
 
Thank you for completing this questionnaire.  Please return it in the enclosed freepost envelope with your consent form, 
contact details and Protecting Your Heart Questionnaire. 
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